Stories
Lupin Launches World First Triple Combination Inhaler For COPD In India
N
News18•06-10-2026, 13:00
Lupin Launches World First Triple Combination Inhaler For COPD In India
- •Lupin Ltd has announced the launch of Formoflo-G MDI, a fixed-dose triple combination metered-dose inhaler for chronic obstructive pulmonary disease in India.
- •The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate into a single twice-daily inhaler following approval from the DCGI.
- •The new therapy aims to help more than 55 million people suffering from COPD in India, where the respiratory condition is a leading cause of death and disability.
- •Lupin currently ranks second in the respiratory therapy segment in India according to recent industry data.
Key Questions Answered
Lupin launched Formoflo-G MDI, a fixed-dose triple combination metered-dose inhaler combining Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for the long-term management of moderate to severe chronic obstructive pulmonary disease in India.
The launch of the Formoflo-G MDI inhaler follows the formal approval granted by the Drug Controller General of India.
According to the company, the newly introduced triple combination therapy aims to serve more than 55 million people living with chronic obstructive pulmonary disease in India.
